Will venetoclax/venetoclax be a new drug included in medical insurance in 2024?

Venetoclax is an oral selective inhibitor of the pro-survival protein BCL-2, which can restore the apoptotic ability of malignant cells. The drug originated from the research collaboration between Abbott Laboratories (now AbbVie) and Genentech, and was jointly developed by AbbVie and Genentec/Roche. It is mainly used to treat hematological malignancies. Veneclat is approved in the United States as monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy for 17p deletion (detected by an FDA-approved test). Veneclat is in the development stage of Phase I-III combination therapy for CLL and can be used as monotherapy and/or combination therapy for the treatment of small lymphocytic leukemia and acute myeloid leukemia.

The original drug of Venecla has been launched in China. According to the information in the "National Medical Insurance (2023 Edition)", as of January 2024, this drug has been included in the Class B medical insurance, only for adults with acute myeloid leukemia. The patients are reimbursed, and the price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, 100mg*112 tablets per box, is priced at more than 10,000 RMB (the price may fluctuate due to exchange rates). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).